Thompson Emmet M, Matsiko Amos, Farrell Eric, Kelly Daniel J, O'Brien Fergal J
Tissue Engineering Research Group, Department of Anatomy, Royal College of Surgeons in Ireland, Dublin, Ireland.
Trinity Centre for Bioengineering, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland.
J Tissue Eng Regen Med. 2015 Aug;9(8):889-902. doi: 10.1002/term.1918. Epub 2014 Jun 11.
Despite its natural healing potential, bone is unable to regenerate sufficient tissue within critical-sized defects, resulting in a non-union of bone ends. As a consequence, interventions are required to replace missing, damaged or diseased bone. Bone grafts have been widely employed for the repair of such critical-sized defects. However, the well-documented drawbacks associated with autografts, allografts and xenografts have motivated the development of alternative treatment options. Traditional tissue engineering strategies have typically attempted to direct in vitro bone-like matrix formation within scaffolds prior to implantation into bone defects, mimicking the embryological process of intramembranous ossification (IMO). Tissue-engineered constructs developed using this approach often fail once implanted, due to poor perfusion, leading to avascular necrosis and core degradation. As a result of such drawbacks, an alternative tissue engineering strategy, based on endochondral ossification (ECO), has begun to emerge, involving the use of in vitro tissue-engineered cartilage as a transient biomimetic template to facilitate bone formation within large defects. This is driven by the hypothesis that hypertrophic chondrocytes can secrete angiogenic and osteogenic factors, which play pivotal roles in both the vascularization of constructs in vivo and the deposition of a mineralized extracellular matrix, with resulting bone deposition. In this context, this review focuses on current strategies taken to recapitulate ECO, using a range of distinct cells, biomaterials and biochemical stimuli, in order to facilitate in vivo bone formation.
尽管骨骼具有天然的愈合潜力,但在临界尺寸的骨缺损中,它无法再生足够的组织,导致骨端不愈合。因此,需要采取干预措施来替代缺失、受损或患病的骨骼。骨移植已被广泛用于修复此类临界尺寸的骨缺损。然而,与自体骨移植、异体骨移植和异种骨移植相关的诸多缺点促使人们开发替代治疗方案。传统的组织工程策略通常试图在将支架植入骨缺损之前,在体外引导类似骨的基质形成,模拟膜内成骨(IMO)的胚胎学过程。使用这种方法开发的组织工程构建体一旦植入往往会失败,原因是灌注不良,导致缺血性坏死和核心降解。由于这些缺点,一种基于软骨内成骨(ECO)的替代组织工程策略开始出现,该策略涉及使用体外组织工程软骨作为临时仿生模板,以促进大尺寸缺损内的骨形成。这一策略的依据是,肥大软骨细胞可以分泌血管生成和成骨因子,这些因子在体内构建体的血管化以及矿化细胞外基质的沉积中都起着关键作用,进而导致骨沉积。在此背景下,本综述重点关注当前为重现ECO所采取的策略,这些策略使用了一系列不同的细胞、生物材料和生化刺激因素,以促进体内骨形成。